

HLC027B – Table of Contents

INTRODUCTION	XXII
STUDY OBJECTIVES	XXII
REASONS FOR DOING THIS STUDY	XXII
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	XXIII
SCOPE OF THE STUDY	XXIII
METHODOLOGY	XXIII
INFORMATION SOURCES	XXIII
ABOUT THE AUTHOR	XXIII
RELATED BCC REPORTS	XXIV
BCC ONLINE SERVICES	XXIV
DISCLAIMER	XXIV
SUMMARY	XXV
SUMMARY TABLE THE GLOBAL CANCER THERAPY MARKET, THROUGH 2013 (\$ MILLIONS)	XXV
SUMMARY FIGURE THE GLOBAL CANCER THERAPY MARKET, 2006-2013 (\$ MILLIONS)	XXVI
OVERVIEW	1
WHAT IS CANCER?	1
CAUSES OF CANCER	1
TYPES OF CANCER	2
BLADDER CANCER	3
Risk Factors	3
Treatment	4
BREAST CANCER	5
Risk Factors	5
Treatment	6
Treatment (continued)	7
COLORECTAL CANCER	8
Risk Factors	8
Treatment	9
ENDOMETRIAL CANCER	10
Risk Factors	10
Treatment	11
KIDNEY CANCER	11
Risk Factors	11
Treatment	12
LEUKEMIA	13
Risk Factors	13
Treatment	14
LUNG CANCER	15
Risk Factors	15
Treatment	16
MELANOMA	17
Risk Factors	17

Treatment	18
NON-HODGKIN'S LYMPHOMA	19
Risk Factors	19
Treatment	19
PANCREATIC CANCER	20
Risk Factors	20
Treatment	21
PROSTATE CANCER	21
Risk Factors	21
Treatment	22
SKIN CANCER	23
Risk Factors	23
Treatment	24
THYROID CANCER	24
Risk Factors	25
Treatment	25
Treatment (Continued)	26
REGULATORY ISSUES	27
NEW DRUG APPROVALS	27
TABLE 1 CANCER DRUGS APPROVED BY THE FDA	27
TABLE 1 (CONTINUED)	28
TABLE 1 (CONTINUED)	29
TABLE 1 (CONTINUED)	30
TABLE 1 (CONTINUED)	31
TABLE 1 (CONTINUED)	32
TABLE 1 (CONTINUED)	33
TABLE 1 (CONTINUED)	34
NEW DRUG APPLICATIONS	34
TABLE 2 NEW DRUG APPLICATIONS (2005 TO JANUARY 2008)	35
RECALLS	35
TABLE 3 RECALLS (2005 TO JANUARY 2008)	36
TABLE 3 (CONTINUED)	37
TABLE 3 (CONTINUED)	38
PREVALENCE	39
WORLDWIDE PREVALENCE	39
TABLE 4 WORLDWIDE PREVALENCE OF CANCER, 2007 (MILLIONS)	39
TABLE 5 WORLDWIDE PREVALENCE OF NEW CASES OF CANCER, BY REGION, 2007	40
TABLE 6 WORLDWIDE DEATHS DUE TO CANCER, BY REGION, 2007	40
PREVALENCE IN THE UNITED STATES	41
TABLE 7 ESTIMATED NEW CANCER CASES IN THE U.S., 2007	41
TABLE 8 CANCER DEATHS IN THE U.S., 2007	42
PREVALENCE IN EUROPE	42
TABLE 9 ESTIMATED NEW CANCER CASES IN EUROPE, 2007	43
TABLE 10 CANCER DEATHS IN EUROPE, 2007	43
CLASSIFICATION OF CANCER THERAPIES	44

CHEMOTHERAPY	44
ALKYLATING AND ALKYLATING-LIKE AGENTS	44
TABLE 11 ALKYLATING AGENTS	45
ANTIMETABOLITES	45
TABLE 12 ANTIMETABOLITES	46
ANTHRACYCLINES	46
TABLE 13 CYTOTOXIC ANTIBIOTIC DRUGS	46
TABLE 13 (CONTINUED)	47
PLANT ALKALOIDS	47
TABLE 14 ALKALOIDS/MITOTIC INHIBITORS	47
TOPOISOMERASE INHIBITORS	48
TABLE 15 TOPOISOMERASE INHIBITORS	48
BIOLOGICAL THERAPY OR IMMUNOTHERAPY	48
INTERFERONS AND OTHER CYTOKINES	49
TABLE 16 INTERFERONS USED IN CANCER THERAPY	49
TABLE 17 INTERLEUKINS USED IN CANCER THERAPY	49
CANCER VACCINES	50
HORMONE THERAPY	50
ANTIESTROGENS	51
TABLE 18 ANTIESTROGENS USED IN CANCER THERAPY	51
AROMATASE INHIBITOR	51
TABLE 19 AROMATASE INHIBITORS USED IN THE TREATMENT OF CANCER	52
ANTIANDROGENS	52
TABLE 20 ANTIANDROGENS USED IN CANCER TREATMENT	52
LUTEINIZING HORMONE-RELEASING HORMONE	52
TABLE 21 LUTEINIZING HORMONE-RELEASING HORMONE USED IN THE TREATMENT OF CANCER	53
TARGETED THERAPY	53
SMALL MOLECULES/CANCER GROWTH INHIBITORS	53
TABLE 22 CANCER GROWTH INHIBITORS	53
TABLE 22 (CONTINUED)	54
MONOCLONAL ANTIBODIES	54
Conjugated	54
Naked	54
TABLE 23 MONOCLONAL ANTIBODIES USED IN THE TREATMENT OF CANCER	55
INDUSTRY STRUCTURE	56
CHEMOTHERAPY	56
ALKYLATING AGENTS	56
TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)	56
FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)	57
ANTHRACYCLINES	57

TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)	57
FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)	58
PLANT ALKALOIDS	58
TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)	58
FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)	59
ANTIMETABOLITES	59
TABLE 27 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)	59
FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)	60
TOPOISOMERASE	60
TABLE 28 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)	60
FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)	61
MARKET LEADERS OF CHEMOTHERAPY	61
TABLE 29 WORLDWIDE MARKET SHARE IN CHEMOTHERAPY, 2007 (%)	62
FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHEMOTHERAPY, 2007 (%)	62
HORMONE THERAPY	63
ANTIESTROGENS	63
TABLE 30 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)	63
FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)	63
ANTIANDROGENS	64
TABLE 31 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)	64
FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIENDROGENS, 2007 (%)	64
AROMATASE INHIBITORS	65
TABLE 32 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)	65
FIGURE 9 SHARES OF MANUFCAATURERS/DISTRIBUTORS FOR AROMATASE INHIBITOR, 2007 (%)	65
LH-RH AGONIST INHIBITORS	66
TABLE 33 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH-RH AGONIST INHIBITORS, 2007 (%)	66
FIGURE 10 SHARES OF MANUFACTURERS/ DISTRIBUTORS FOR LH RH AGONIST INHIBITORS, 2007 (%)	66
MARKET LEADERS OF HORMONE THERAPY	67

TABLE 34 WORLDWIDE MARKET SHARE IN HORMONE THERAPY, 2007 (%)
67

FIGURE 11 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR HORMONE THERAPY, 2007 (%) 67

TARGETED THERAPY 68

MONOCLONAL ANTIBODIES 68

TABLE 35 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%) 68

FIGURE 12 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%) 68

SMALL MOLECULES 69

TABLE 36 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%) 69

FIGURE 13 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%) 69

MARKET LEADERS OF TARGET THERAPY 70

TABLE 37 WORLDWIDE MARKET SHARE IN TARGET THERAPY, 2007 (%)
70

FIGURE 14 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TARGET THERAPY, 2007 (%) 70

IMMUNOTHERAPY 71

INTERFERON AND CYTOKINES 71

TABLE 38 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%) 71

FIGURE 15 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%) 71

CANCER VACCINES 72

TABLE 39 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%) 72

FIGURE 16 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%) 72

MARKET LEADERS OF IMMUNOTHERAPY 72

TABLE 40 WORLDWIDE MARKET SHARE IN IMMUNOTHERAPY, 2007 (%)
73

FIGURE 17 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR IMMUNOTHERAPY, 2007 (%) 73

DEMAND AND USE 74

FACTORS AFFECTING SALES OF CANCER DRUGS 74

Competition 74

Pricing/Cost 75

MAJOR FACTORS FOR FUTURE GROWTH 75

Life Expectancy 75

Patent Protection 76

Drug Portfolio Management 76

Significant Potential of Developing Countries 76

FUTURE OF THE CANCER MARKET 76

Chemotherapy Will Sustain	76
Targeted Therapy dominates	77
Patent Expiries	77
STRATEGIES OF BIG PHARMACEUTICAL COMPANIES	77
Enhancement in Production Capacity:	78
Market Strategy	78
Mergers, Acquisitions, and Collaborations	78
Further Investigations	78
MARKET ANALYSIS	79
CHEMOTHERAPY	79
CHEMOTHERAPY (CONTINUED)	80
Market Size	81
TABLE 41 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, THROUGH 2013 (\$ MILLIONS)	81
FIGURE 18 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, 2006-2013 (\$ MILLIONS)	82
TABLE 42 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)	82
FIGURE 19 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)	83
ALKYLATING AGENTS	84
TABLE 43 GLOBAL SALES OF ALKYLATING AGENTS, THROUGH 2013 (\$ MILLIONS)	84
FIGURE 20 GLOBAL SALES OF ALKYLATING AGENTS, 2006-2013 (\$ MILLIONS)	84
ANTHRACYCLINES	85
TABLE 44 GLOBAL SALES OF ANTHRACYCLINES, THROUGH 2013 (\$ MILLIONS)	85
FIGURE 21 GLOBAL SALES OF ANTHRACYCLINES, 2006-2013 (\$ MILLIONS)	86
PLANT ALKALOIDS	86
TABLE 45 GLOBAL SALES OF PLANT ALKALOIDS, THROUGH 2013 (\$ MILLIONS)	87
FIGURE 22 GLOBAL SALES OF PLANT ALKALOIDS, 2006-2013 (\$ MILLIONS)	87
ANTIMETABOLITES	88
TABLE 46 GLOBAL SALES OF ANTIMETABOLITES, THROUGH 2013 (\$ MILLIONS)	88
FIGURE 23 GLOBAL SALES OF ANTIMETABOLITES, 2006-2013 (\$ MILLIONS)	89
TOPOISOMERASE INHIBITORS	89
TABLE 47 GLOBAL SALES OF TOPOISOMERASE INHIBITORS, THROUGH 2013 (\$ MILLIONS)	90
FIGURE 24 GLOBAL SALES OF TOPISOMERASE INHIBITORS, 2006-2013 (\$ MILLIONS)	90
HORMONE THERAPY	91

Market Size	92
TABLE 48 GLOBAL SALES OF HORMONE THERAPIES, THROUGH 2013 (\$ MILLIONS)	92
FIGURE 25 GLOBAL SALES OF HORMONE THERAPIES, 2006-2013 (\$ MILLIONS)	92
TABLE 49 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)	93
FIGURE 26 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)	93
ANTIESTROGENS	93
TABLE 50 GLOBAL SALES OF ANTIESTROGENS, THROUGH 2013 (\$ MILLIONS)	94
FIGURE 27 GLOBAL SALES OF ANTIESTROGENS, 2006-2013 (\$ MILLIONS)	94
ANTIANDROGENS	95
TABLE 51 GLOBAL SALES OF ANTIANDROGENS, THROUGH 2013 (\$ MILLIONS)	95
FIGURE 28 GLOBAL SALES OF ANTIANDROGENS, 2006-2013 (\$ MILLIONS)	96
AROMATASE INHIBITORS	96
TABLE 52 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 (\$ MILLIONS)	97
FIGURE 29 GLOBAL SALES OF AROMATASE INHIBITORS, 2006-2013 (\$ MILLIONS)	97
LH-RH AGONISTS	98
TABLE 53 GLOBAL SALES OF LH-RH AGONISTS, THROUGH 2013 (\$ MILLIONS)	98
FIGURE 30 GLOBAL SALES OF LH-RH AGONISTS, 2006-2013 (\$ MILLIONS)	99
TARGET THERAPIES	100
Market Size	101
TABLE 54 GLOBAL SALES OF TARGET THERAPY CANCER PRODUCTS, THROUGH 2013 (\$ MILLIONS)	102
FIGURE 31 WORLDWIDE SALES OF TARGET THERAPY CANCER PRODUCTS, 2006-2013 (\$ MILLIONS)	102
TABLE 55 GLOBAL SHARE OF TARGETED THERAPY, BY TYPE, 2007 (%)	103
FIGURE 32 GLOBAL SHARE OF TARGET THERAPY, BY TYPE, 2007 (%)	103
MONOCLONAL ANTIBODIES	103
TABLE 56 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2013 (\$ MILLIONS)	104
FIGURE 33 GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2006-2013 (\$ MILLIONS)	104
SMALL MOLECULES	105
TABLE 57 GLOBAL SALES OF SMALL MOLECULES, THROUGH 2013 (\$ MILLIONS)	105

FIGURE 34 GLOBAL SALES OF SMALL MOLECULES, 2006-2013	(\$ MILLIONS)	106
IMMUNOTHERAPY 106		
Market Size 107		
TABLE 58 GLOBAL SALES OF IMMUNOTHERAPY PRODUCTS, THROUGH 2013 (\$ MILLIONS)		107
FIGURE 35 WORLDWIDE SALES OF IMMUNOTHERAPY PRODUCTS, 2006-2013 (\$ MILLIONS)		108
TABLE 59 GLOBAL REVENUE SHARE OF IMMUNOTHERAPY BY TYPE, 2007 (%)		108
FIGURE 36 GLOBAL SHARE OF IMMUNOTHERAPY, BY TYPE, 2007 (%)		109
INTERFERONS AND CYTOKINES 109		
TABLE 60 GLOBAL SALES OF INTERFERONS AND CYTOKINES, THROUGH 2013 (\$ MILLIONS)		110
FIGURE 37 GLOBAL SALES OF INTERFERONS AND CYTOKINES, 2006-2013 (\$ MILLIONS)		110
VACCINES 111		
TABLE 61 GLOBAL SALES OF CANCER VACCINES, THROUGH 2013 (\$ MILLIONS)		111
FIGURE 38 GLOBAL SALES OF CANCER VACCINES, 2006-2013	(\$ MILLIONS)	112
NEW DEVELOPMENTS 113		
TABLE 62 CANCER DRUG PIPELINE IN PHASE III CLINICAL TRIALS		113
TABLE 62 (CONTINUED)		114
TABLE 62 (CONTINUED)		115
TABLE 62 (CONTINUED)		116
TARGET 116		
TABLE 63 CANCER DRUG PIPELINE IN PHASE II CLINICAL TRIALS		116
TABLE 63 (CONTINUED)		117
TABLE 63 (CONTINUED)		118
TABLE 63 (CONTINUED)		119
TABLE 64 CANCER DRUG PIPELINE IN PHASE I CLINICAL TRIALS		120
TABLE 64 (CONTINUED)		121
TABLE 64 (CONTINUED)		122
MARKET BY DISEASE TYPE 123		
TABLE 65 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, THROUGH 2013 (\$ MILLIONS)		123
FIGURE 39 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, 2006-2013 (\$ MILLIONS)		124
TABLE 66 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)		124
FIGURE 40 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)		125
BREAST CANCER THERAPY 125		
TABLE 67 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 (\$ MILLION/%)		126
FIGURE 41 SALES OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 (\$ MILLIONS)		126

TABLE 68	WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)	127
FIGURE 42	WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)	127
	COLORECTAL CANCER	128
TABLE 69	SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007	(\$ MILLION/%) 128
FIGURE 43	SALES OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 (\$ MILLIONS)	129
TABLE 70	WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)	129
FIGURE 44	WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)	130
	PROSTATE CANCER	130
TABLE 71	SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 (\$ MILLION/%)	131
FIGURE 45	SALES OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 (\$ MILLIONS)	131
TABLE 72	WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)	132
FIGURE 46	WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)	132
	NONSMALL CELL LUNG CANCER	132
TABLE 73	GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 (\$ MILLIONS/%)	133
FIGURE 47	GLOBAL SALES OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007	(\$ MILLIONS) 133
TABLE 74	GLOBAL MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)	134
FIGURE 48	WORLDWIDE MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)	134
	HEAD AND NECK CANCER	135
TABLE 75	GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 (\$ MILLION/%)	135
FIGURE 49	GLOBAL SALES OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 (\$ MILLIONS)	135
TABLE 76	WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)	136
FIGURE 50	WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)	136
	RENAL CELL CARCINOMA	137
TABLE 77	GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 (\$ MILLIONS/%)	137

FIGURE 51 GLOBAL SALES OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 (\$ MILLIONS)	137
TABLE 78 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)	138
FIGURE 52 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)	138
PANCREATIC CANCER THERAPY	139
TABLE 79 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 (\$ MILLION/%)	139
FIGURE 53 GLOBAL SALES OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 (\$ MILLIONS)	139
TABLE 80 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)	140
FIGURE 54 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)	140
PATENT ANALYSIS	141
TOTAL PATENTS	141
PATENTS BY YEAR	141
TABLE 81 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2008	142
FIGURE 55 NUMBER OF PATENTS, 2005-2008	142
PATENTS BY TYPE	142
TABLE 82 NUMBER OF PATENTS BY TYPE, 2005-2008	143
FIGURE 56 NUMBER OF PATENTS BY TYPE, 2005-2008 (NO. OF PATENTS)	143
FIGURE 57 NUMBER OF PATENTS, SHARE BY TYPE, 2005-2008 (%)	144
PATENTS BY COUNTRY	144
TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008	144
TABLE 83 (CONTINUED)	145
PATENTS BY COMPANY	145
TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005-2008	146
TABLE 84 (CONTINUED)	147
TABLE 84 (CONTINUED)	148
PATENTS BY ASSIGNEE	149
TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005-2008	149
COMPANY PROFILES	150
ABRAXIS BIOSCIENCES, INC.	150
AMGEN INC.	150
ASTRAZENECA PLC	151
BIOGEN IDEC	152
BRISTOL-MYERS SQUIBB	153
CELGENE CORP.	153
CEPHALON INC.	154
CHUGAI PHARMACEUTICAL CO., LTD.	154
ELI LILLY AND CO.	155
GENENTECH INC.	155
GENENTECH INC. (CONTINUED)	156

GENZYME CORP.	157
GLAXOSMITHKLINE PLC	158
GPC BIOTECH AG	159
IMCLONE SYSTEMS, INC.	159
INFINITY PHARMACEUTICALS, INC.	159
MERCK & CO.	160
NOVARTIS	160
OSI PHARMACEUTICALS, INC.	161
PFIZER INC.	161
PROGEN PHARMACEUTICALS, LTD.	162
ROCHE	162
SANOFI-AVENTIS	163
SCHERING-PLOUGH	163
SEATTLE GENETICS, INC.	164
TAP PHARMACEUTICAL PRODUCTS, INC.	165
TAIHO PHARMACEUTICALS CO., LTD.	165
WYETH	166
YM BIOSCIENCES, INC.	166
APPENDIX	167
APPENDIX	167
APPENDIX (CONTINUED)	168

SUMMARY TABLE THE GLOBAL CANCER THERAPY MARKET, THROUGH 2013 (\$ MILLIONS) XXV

TABLE 1	CANCER DRUGS APPROVED BY THE FDA	27
TABLE 2	NEW DRUG APPLICATIONS (2005 TO JANUARY 2008)	35
TABLE 3	RECALLS (2005 TO JANUARY 2008)	36
TABLE 4	WORLDWIDE PREVALENCE OF CANCER, 2007 (MILLIONS)	39
TABLE 5	WORLDWIDE PREVALENCE OF NEW CASES OF CANCER, BY REGION, 2007	40
TABLE 6	WORLDWIDE DEATHS DUE TO CANCER, BY REGION, 2007	40
TABLE 7	ESTIMATED NEW CANCER CASES IN THE U.S., 2007	41
TABLE 8	CANCER DEATHS IN THE U.S., 2007	42
TABLE 9	ESTIMATED NEW CANCER CASES IN EUROPE, 2007	43
TABLE 10	CANCER DEATHS IN EUROPE, 2007	43
TABLE 11	ALKYLATING AGENTS	45
TABLE 12	ANTIMETABOLITES	46
TABLE 13	CYTOTOXIC ANTIBIOTIC DRUGS	46
TABLE 14	ALKALOIDS/MITOTIC INHIBITORS	47
TABLE 15	TOPOISOMERASE INHIBITORS	48
TABLE 16	INTERFERONS USED IN CANCER THERAPY	49
TABLE 17	INTERLEUKINS USED IN CANCER THERAPY	49
TABLE 18	ANTIESTROGENS USED IN CANCER THERAPY	51
TABLE 19	AROMATASE INHIBITORS USED IN THE TREATMENT OF CANCER	

TABLE 20 ANTIANDROGENS USED IN CANCER TREATMENT	52
TABLE 21 LUTEINIZING HORMONE-RELEASING HORMONE USED IN THE TREATMENT OF CANCER	53
TABLE 22 CANCER GROWTH INHIBITORS	53
TABLE 23 MONOCLONAL ANTIBODIES USED IN THE TREATMENT OF CANCER	55
TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)	56
TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)	57
TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)	58
TABLE 27 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)	59
TABLE 28 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)	60
TABLE 29 WORLDWIDE MARKET SHARE IN CHEMOTHERAPY, 2007 (%)	62
TABLE 30 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)	63
TABLE 31 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)	64
TABLE 32 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)	65
TABLE 33 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH-RH AGONIST INHIBITORS, 2007 (%)	66
TABLE 34 WORLDWIDE MARKET SHARE IN HORMONE THERAPY, 2007 (%)	67
TABLE 35 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)	68
TABLE 36 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)	69
TABLE 37 WORLDWIDE MARKET SHARE IN TARGET THERAPY, 2007 (%)	70
TABLE 38 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)	71
TABLE 39 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)	72
TABLE 40 WORLDWIDE MARKET SHARE IN IMMUNOTHERAPY, 2007 (%)	73
TABLE 41 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, THROUGH 2013 (\$ MILLIONS)	81
TABLE 42 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)	82
TABLE 43 GLOBAL SALES OF ALKYLATING AGENTS, THROUGH 2013 (\$ MILLIONS)	84

TABLE 44 GLOBAL SALES OF ANTHRACYCLINES, THROUGH 2013 (\$ MILLIONS)	85
TABLE 45 GLOBAL SALES OF PLANT ALKALOIDS, THROUGH 2013 (\$ MILLIONS)	87
TABLE 46 GLOBAL SALES OF ANTIMETABOLITES, THROUGH 2013 (\$ MILLIONS)	88
TABLE 47 GLOBAL SALES OF TOPOISOMERASE INHIBITORS, THROUGH 2013 (\$ MILLIONS)	90
TABLE 48 GLOBAL SALES OF HORMONE THERAPIES, THROUGH 2013 (\$ MILLIONS)	92
TABLE 49 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)	93
TABLE 50 GLOBAL SALES OF ANTIESTROGENS, THROUGH 2013 (\$ MILLIONS)	94
TABLE 51 GLOBAL SALES OF ANTIANDROGENS, THROUGH 2013 (\$ MILLIONS)	95
TABLE 52 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 (\$ MILLIONS)	97
TABLE 53 GLOBAL SALES OF LH-RH AGONISTS, THROUGH 2013 (\$ MILLIONS)	98
TABLE 54 GLOBAL SALES OF TARGET THERAPY CANCER PRODUCTS, THROUGH 2013 (\$ MILLIONS)	102
TABLE 55 GLOBAL SHARE OF TARGETED THERAPY, BY TYPE, 2007 (%)	103
TABLE 56 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2013 (\$ MILLIONS)	104
TABLE 57 GLOBAL SALES OF SMALL MOLECULES, THROUGH 2013 (\$ MILLIONS)	105
TABLE 58 GLOBAL SALES OF IMMUNOTHERAPY PRODUCTS, THROUGH 2013 (\$ MILLIONS)	107
TABLE 59 GLOBAL REVENUE SHARE OF IMMUNOTHERAPY BY TYPE, 2007 (%)	108
TABLE 60 GLOBAL SALES OF INTERFERONS AND CYTOKINES, THROUGH 2013 (\$ MILLIONS)	110
TABLE 61 GLOBAL SALES OF CANCER VACCINES, THROUGH 2013 (\$ MILLIONS)	111
TABLE 62 CANCER DRUG PIPELINE IN PHASE III CLINICAL TRIALS	113
TABLE 63 CANCER DRUG PIPELINE IN PHASE II CLINICAL TRIALS	116
TABLE 64 CANCER DRUG PIPELINE IN PHASE I CLINICAL TRIALS	120
TABLE 65 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, THROUGH 2013 (\$ MILLIONS)	123
TABLE 66 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)	124
TABLE 67 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 (\$ MILLION/%)	126
TABLE 68 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)	127

TABLE 69 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 (\$ MILLION/%)	128
TABLE 70 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)	129
TABLE 71 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 (\$ MILLION/%)	131
TABLE 72 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)	132
TABLE 73 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 (\$ MILLION/%)	133
TABLE 74 GLOBAL MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)	134
TABLE 75 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 (\$ MILLION/%)	135
TABLE 76 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)	136
TABLE 77 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 (\$ MILLION/%)	137
TABLE 78 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)	138
TABLE 79 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 (\$ MILLION/%)	139
TABLE 80 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)	140
TABLE 81 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2008	142
TABLE 82 NUMBER OF PATENTS BY TYPE, 2005-2008	143
TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008	144
TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005-2008	146
TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005-2008	149
SUMMARY FIGURE THE GLOBAL CANCER THERAPY MARKET, 2006-2013 (\$ MILLIONS) XXVI	
FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)	57
FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)	58
FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)	59
FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)	60
FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)	61

FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHEMOTHERAPY, 2007 (%)	62	
FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)	63	
FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)	64	
FIGURE 9 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITOR, 2007 (%)	65	
FIGURE 10 SHARES OF MANUFACTURERS/ DISTRIBUTORS FOR LH RH AGONIST INHIBITORS, 2007 (%)	66	
FIGURE 11 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR HORMONE THERAPY, 2007 (%)	67	
FIGURE 12 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)	68	
FIGURE 13 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)	69	
FIGURE 14 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TARGET THERAPY, 2007 (%)	70	
FIGURE 15 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)	71	
FIGURE 16 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)	72	
FIGURE 17 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR IMMUNOTHERAPY, 2007 (%)	73	
FIGURE 18 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, 2006-2013 (\$ MILLIONS)	82	
FIGURE 19 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)	83	
FIGURE 20 GLOBAL SALES OF ALKYLATING AGENTS, 2006-2013 (\$ MILLIONS)	84	
FIGURE 21 GLOBAL SALES OF ANTHRACYCLINES, 2006-2013 (\$ MILLIONS)	86	
FIGURE 22 GLOBAL SALES OF PLANT ALKALOIDS, 2006-2013 (\$ MILLIONS)	87	
FIGURE 23 GLOBAL SALES OF ANTIMETABOLITES, 2006-2013 (\$ MILLIONS)	89	
FIGURE 24 GLOBAL SALES OF TOPISOMERASE INHIBITORS, 2006-2013 (\$ MILLIONS)	90	
FIGURE 25 GLOBAL SALES OF HORMONE THERAPIES, 2006-2013 (\$ MILLIONS)	92	
FIGURE 26 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)	93	
FIGURE 27 GLOBAL SALES OF ANTIESTROGENS, 2006-2013 (\$ MILLIONS)	94	
FIGURE 28 GLOBAL SALES OF ANTIANDROGENS, 2006-2013 (\$ MILLIONS)	96	

FIGURE 29 GLOBAL SALES OF AROMATASE INHIBITORS, 2006-2013 (\$ MILLIONS)	97
FIGURE 30 GLOBAL SALES OF LH-RH AGONISTS, 2006-2013 (\$ MILLIONS)	99
FIGURE 31 WORLDWIDE SALES OF TARGET THERAPY CANCER PRODUCTS, 2006-2013 (\$ MILLIONS)	102
FIGURE 32 GLOBAL SHARE OF TARGET THERAPY, BY TYPE, 2007 (%)	103
FIGURE 33 GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2006-2013 (\$ MILLIONS)	104
FIGURE 34 GLOBAL SALES OF SMALL MOLECULES, 2006-2013 (\$ MILLIONS)	106
FIGURE 35 WORLDWIDE SALES OF IMMUNOTHERAPY PRODUCTS, 2006-2013 (\$ MILLIONS)	108
FIGURE 36 GLOBAL SHARE OF IMMUNOTHERPY, BY TYPE, 2007 (%)	109
FIGURE 37 GLOBAL SALES OF INTERFERONS AND CYTOKINES, 2006-2013 (\$ MILLIONS)	110
FIGURE 38 GLOBAL SALES OF CANCER VACCINES, 2006-2013 (\$ MILLIONS)	112
FIGURE 39 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, 2006-2013 (\$ MILLIONS)	124
FIGURE 40 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)	125
FIGURE 41 SALES OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 (\$ MILLIONS)	126
FIGURE 42 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)	127
FIGURE 43 SALES OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 (\$ MILLIONS)	129
FIGURE 44 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)	130
FIGURE 45 SALES OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 (\$ MILLIONS)	131
FIGURE 46 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)	132
FIGURE 47 GLOBAL SALES OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 (\$ MILLIONS)	133
FIGURE 48 WORLDWIDE MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)	134
FIGURE 49 GLOBAL SALES OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 (\$ MILLIONS)	135
FIGURE 50 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)	136
FIGURE 51 GLOBAL SALES OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 (\$ MILLIONS)	137
FIGURE 52 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)	138

FIGURE 53 GLOBAL SALES OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 (\$ MILLIONS)	139
FIGURE 54 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)	140
FIGURE 55 NUMBER OF PATENTS, 2005-2008	142
FIGURE 56 NUMBER OF PATENTS BY TYPE, 2005-2008 (NO. OF PATENTS)	143
FIGURE 57 NUMBER OF PATENTS, SHARE BY TYPE, 2005-2008 (%)	144